Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 2
1977 1
1978 2
1980 6
1981 3
1982 5
1983 9
1984 9
1985 15
1986 23
1987 16
1988 26
1989 22
1990 32
1991 27
1992 42
1993 35
1994 40
1995 54
1996 72
1997 72
1998 68
1999 69
2000 70
2001 92
2002 92
2003 94
2004 117
2005 115
2006 134
2007 148
2008 145
2009 190
2010 180
2011 184
2012 197
2013 211
2014 231
2015 224
2016 229
2017 239
2018 277
2019 285
2020 302
2021 297
2022 316
2023 233
2024 70

Text availability

Article attribute

Article type

Publication date

Search Results

4,787 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "MOGS-congenital disorder of glycosylation"
Page 1
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.
Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, Yu X. Luo G, et al. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188409. doi: 10.1016/j.bbcan.2020.188409. Epub 2020 Aug 19. Biochim Biophys Acta Rev Cancer. 2021. PMID: 32827580 Review.
Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker, predictor, and promoter in pancreatic cancer. ...As a promoter, CA19-9 could be used to evaluate the biology …
Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an indicator of aberrant glycosylation in pancreatic cancer. C …
International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.
Altassan R, Péanne R, Jaeken J, Barone R, Bidet M, Borgel D, Brasil S, Cassiman D, Cechova A, Coman D, Corral J, Correia J, de la Morena-Barrio ME, de Lonlay P, Dos Reis V, Ferreira CR, Fiumara A, Francisco R, Freeze H, Funke S, Gardeitchik T, Gert M, Girad M, Giros M, Grünewald S, Hernández-Caselles T, Honzik T, Hutter M, Krasnewich D, Lam C, Lee J, Lefeber D, Marques-de-Silva D, Martinez AF, Moravej H, Õunap K, Pascoal C, Pascreau T, Patterson M, Quelhas D, Raymond K, Sarkhail P, Schiff M, Seroczyńska M, Serrano M, Seta N, Sykut-Cegielska J, Thiel C, Tort F, Vals MA, Videira P, Witters P, Zeevaert R, Morava E. Altassan R, et al. J Inherit Metab Dis. 2019 Jan;42(1):5-28. doi: 10.1002/jimd.12024. J Inherit Metab Dis. 2019. PMID: 30740725
Phosphomannomutase 2 (PMM2-CDG) is the most common congenital disorder of N-glycosylation and is caused by a deficient PMM2 activity. ...
Phosphomannomutase 2 (PMM2-CDG) is the most common congenital disorder of N-glycosylation and is caused by a deficient PMM2 ac …
Congenital disorders of glycosylation: narration of a story through its patents.
Monticelli M, D'Onofrio T, Jaeken J, Morava E, Andreotti G, Cubellis MV. Monticelli M, et al. Orphanet J Rare Dis. 2023 Aug 29;18(1):247. doi: 10.1186/s13023-023-02852-w. Orphanet J Rare Dis. 2023. PMID: 37644541 Free PMC article. Review.
Congenital disorders of glycosylation are a group of more than 160 rare genetic defects in protein and lipid glycosylation. ...
Congenital disorders of glycosylation are a group of more than 160 rare genetic defects in protein and lipid glycosylation …
Congenital disorders of glycosylation and infantile epilepsy.
Lee HF, Chi CS. Lee HF, et al. Epilepsy Behav. 2023 May;142:109214. doi: 10.1016/j.yebeh.2023.109214. Epub 2023 Apr 21. Epilepsy Behav. 2023. PMID: 37086590 Review.
Congenital disorders of glycosylation (CDG) are a group of rare inherited metabolic disorders caused by defects in various defects of protein or lipid glycosylation pathways. ...
Congenital disorders of glycosylation (CDG) are a group of rare inherited metabolic disorders caused by defects in vari …
Perspectives on Glycosylation and Its Congenital Disorders.
Ng BG, Freeze HH. Ng BG, et al. Trends Genet. 2018 Jun;34(6):466-476. doi: 10.1016/j.tig.2018.03.002. Epub 2018 Mar 29. Trends Genet. 2018. PMID: 29606283 Free PMC article. Review.
Congenital disorders of glycosylation (CDG) are a rapidly expanding group of metabolic disorders that result from abnormal protein or lipid glycosylation. ...We highlight recent advancements that have resulted in a better understanding of human glyc …
Congenital disorders of glycosylation (CDG) are a rapidly expanding group of metabolic disorders that result from abnor …
Platelets and Defective N-Glycosylation.
Mammadova-Bach E, Jaeken J, Gudermann T, Braun A. Mammadova-Bach E, et al. Int J Mol Sci. 2020 Aug 6;21(16):5630. doi: 10.3390/ijms21165630. Int J Mol Sci. 2020. PMID: 32781578 Free PMC article. Review.
Defects in N-glycosylation and O-glycosylation constitute the largest CDG groups. ...In this review, we highlight normal and deficient N-glycosylation of platelet-derived molecules and discuss the involvement of platelets in the congenital disorders of …
Defects in N-glycosylation and O-glycosylation constitute the largest CDG groups. ...In this review, we highlight normal and d …
What is new in CDG?
Jaeken J, Péanne R. Jaeken J, et al. J Inherit Metab Dis. 2017 Jul;40(4):569-586. doi: 10.1007/s10545-017-0050-6. Epub 2017 May 8. J Inherit Metab Dis. 2017. PMID: 28484880 Review.
Congenital disorders of glycosylation (CDG) are one group among the disorders of glycosylation. ...Genetic diseases with hypoglycosylation can be divided in primary congenital disorders of glycosylation (CDG) and in genetic diseases causi …
Congenital disorders of glycosylation (CDG) are one group among the disorders of glycosylation. ...Genetic disea …
The role of protein glycosylation in the occurrence and outcome of acute ischemic stroke.
Li J, Qiu Y, Zhang C, Wang H, Bi R, Wei Y, Li Y, Hu B. Li J, et al. Pharmacol Res. 2023 May;191:106726. doi: 10.1016/j.phrs.2023.106726. Epub 2023 Mar 11. Pharmacol Res. 2023. PMID: 36907285 Free article. Review.
Drugs targeting glycosylation in the occurrence and progression of stroke may represent a novel therapeutic idea. In this review, we focus on possible perspectives about how glycosylation affects the occurrence and outcome of AIS. We then propose the potential of …
Drugs targeting glycosylation in the occurrence and progression of stroke may represent a novel therapeutic idea. In this review, we …
Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration.
Moll T, Shaw PJ, Cooper-Knock J. Moll T, et al. Brain. 2020 May 1;143(5):1332-1340. doi: 10.1093/brain/awz358. Brain. 2020. PMID: 31724708 Free PMC article. Review.
Our work is the first evidence that isolated dysfunction of a glycosyltransferase is sufficient to cause a neurodegenerative disease, but connection between neurodegeneration and genetic variation within glycosyltransferases is not new. Previous studies have identified ass …
Our work is the first evidence that isolated dysfunction of a glycosyltransferase is sufficient to cause a neurodegenerative disease, …
Nutrition interventions in congenital disorders of glycosylation.
Boyer SW, Johnsen C, Morava E. Boyer SW, et al. Trends Mol Med. 2022 Jun;28(6):463-481. doi: 10.1016/j.molmed.2022.04.003. Epub 2022 May 10. Trends Mol Med. 2022. PMID: 35562242 Free PMC article. Review.
Congenital disorders of glycosylation (CDG) are a group of more than 160 inborn errors of metabolism affecting multiple pathways of protein and lipid glycosylation. ...We review the dietary management in CDG with a focus on two subgroups: N-linked glycosyl …
Congenital disorders of glycosylation (CDG) are a group of more than 160 inborn errors of metabolism affecting multiple pathwa …
4,787 results